MRgFUS thalamotomy for the treatment of tremor: evaluation of learning curve and operator’s experience impact on the procedural and clinical outcome - Scorecard - MDSpire
Advertisement
MRgFUS thalamotomy for the treatment of tremor: evaluation of learning curve and operator’s experience impact on the procedural and clinical outcome
Clinical Scorecard: Assessing the Learning Curve and Impact of Operator Experience on Procedural and Clinical Outcomes in MRgFUS Thalamotomy for Tremor Management
At a Glance
Category
Detail
Condition
Disabling tremor in Essential Tremor (ET) and tremorigenic Parkinson’s Disease (PD)
Key Mechanisms
Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS) Vim thalamotomy uses high-intensity focused ultrasound to ablate specific thalamic nuclei through the intact skull
Target Population
Patients with disabling tremor refractory to drug therapy, median age 70 years, including ET and PD patients
Care Setting
Multidisciplinary clinical setting involving neuroradiologists, neurologists, and neurosurgeons, performed in specialized institutions with MRI and focused ultrasound technology
Key Highlights
MRgFUS Vim thalamotomy is a minimally invasive, FDA-approved treatment for tremor in ET and PD patients.
Operator experience and learning curve significantly impact procedural efficiency and clinical outcomes.
Clinical selection by neurologists expert in movement disorders.
Use of Fahn-Tolosa-Marin scale (FTM) to assess tremor severity pre- and post-treatment.
Assessment of skull density ratio (SDR > 0.3) via CT to determine treatment suitability.
Management
Patient preparation includes scalp trichotomy, premedication (paracetamol, cortisone, ondansetron), and stereotactic frame placement.
Pre-treatment planning involves MRI and CT image fusion for target identification and ultrasound beam path planning.
Treatment involves staged sonications: alignment (low energy), confirmation (increasing energy), and ablation to achieve neuromodulation and lesioning.
Monitoring & Follow-up
Intraprocedural clinical assessment for tremor response and adverse effects.
Use of fiducial markers to monitor head movement during treatment.
Follow-up evaluation of tremor relapse by comparing FTM scores at 24 hours and subsequent visits.
Risks
Potential thalamotomy-related complications include paresthesia, postural instability, transient hemiparesis, ataxia, dysarthria, motor and facial deficits, painful dystonia, and strength deficits on the treated side.
Patient & Prescribing Data
90 patients with disabling tremor refractory to medication (38 ET, 52 PD), median age 70 years, treated unilaterally.
Treatment groups divided by time to assess learning curve; operator experience correlates with improved procedural parameters and clinical outcomes.
Clinical Best Practices
Ensure multidisciplinary team involvement with neuroradiologists as primary operators supported by neurologists and neurosurgeons.
Perform thorough pre-treatment imaging fusion and planning to identify no-pass zones and optimize ultrasound beam targeting.
Monitor patient clinical status continuously during sonications to adjust target and minimize adverse effects.
Evaluate skull density ratio pre-treatment to confirm patient eligibility.
Use standardized tremor rating scales for baseline and follow-up assessments to detect treatment efficacy and relapse.
by F. Bruno, E. Tommasino, L. Pertici, V. Pagliei, A. Gagliardi, A. Catalucci, F. Arrigoni, P. Palumbo, P. Sucapane, F. Pistoia, C. Marini, A. Ricci, A. Barile, E. Di Cesare, A. Splendiani, C. Masciocchi
Baptist Health Miami Neuroscience Institute invites Dr. Aviva Abosch to discuss innovation, leadership, and discovery in the Marie Curie Women in Neuroscience Lectureship.
